GlassScriptPhysician profile
Janet E Orozco
NPI 1285745091
$2,106.10
in general payments reported to CMS, 2019-2025
23 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $151 · 2023: $75.20 · 2024: $922 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $482.96 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $216.44 | 2024 | Inceptiv, Intellis Adaptivestim |
| Nevro Corp. | $173.60 | 2024 | Senza |
| Boston Scientific Corporation | $165.14 | 2021-2024 | |
| Spinal Simplicity, LLC | $161.71 | 2024-2025 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $128.72 | 2021-2025 | Xtampza, Belbuca |
| Amgen INC. | $88.15 | 2022-2024 | Evenity, Prolia |
| Pacira Therapeutics, INC. | $74.36 | 2021 | |
| Hikma Pharmaceuticals USA | $74.06 | 2021-2022 | |
| Novo Nordisk INC | $70.77 | 2024-2025 | Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $68.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $57.37 | 2021 | |
| Averitas Pharma INC. | $51.44 | 2024-2025 | Qutenza |
| Astellas Pharma US INC | $48.07 | 2025 | Veozah |
| Scilex Pharmaceuticals INC. | $39.54 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.76 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.73 | 2021-2025 | Xifaxan |
| Foundation Fusion Solutions, LLC | $32.99 | 2024-2025 | |
| Painteq LLC | $21.67 | 2024 | Painteq |
| Redhill Biopharma INC. | $21.42 | 2021 | |
| Corcept Therapeutics | $20.61 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $18.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.25 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Orozco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.